Summary & Overview
CPT 68841: Lacrimal Duct Drug-Delivery Implantation
CPT code 68841 denotes the insertion of a controlled-release drug implant into the lacrimal ducts, with optional dilation of the duct, to manage ocular inflammation, glaucoma, or related conditions. This targeted, sustained-delivery approach can reduce the need for frequent topical dosing and may alter clinical workflows for ophthalmology practices and ambulatory surgical centers. Nationally, procedures using lacrimal duct drug-delivery implants are of interest for their clinical implications in chronic eye disease management and for payers assessing coverage of novel sustained-release devices.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what CPT code 68841 represents, typical sites of service, and the clinical context for use. The publication summarizes coverage and billing considerations across major payers, highlights common billing modifiers and coding practices where applicable, and provides benchmark references and policy updates relevant to sustained ocular drug-delivery implants. The content is intended to support coding staff, practice managers, and policy analysts in understanding the code’s clinical purpose and administrative implications at a national level.
Data not available in the input: associated taxonomies, specific ICD-10 diagnoses, payer-specific coverage rules, and related codes.
Billing Code Overview
CPT code 68841 describes the insertion of an implant that delivers a drug at a controlled rate into the lacrimal ducts of the eye. The procedure may include dilation of the lacrimal duct and is performed to treat inflammatory eye conditions, glaucoma, or other local ocular disorders requiring sustained drug delivery.
-
Service type: Implantation of a drug-delivery device into the lacrimal (tear) duct with possible duct dilation
-
Typical site of service: Ophthalmology or ambulatory surgical setting, often performed in an outpatient clinic or operating room depending on patient needs and device complexity
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting to an ophthalmology or oculoplastic clinic with chronic ocular surface inflammation or glaucoma refractory to topical therapy, or with inadequate drug delivery due to poor adherence. The patient has symptoms of persistent ocular irritation, conjunctival inflammation, or elevated intraocular pressure despite medications. After evaluation including history, slit-lamp exam, and intraocular pressure measurement, the clinician discusses sustained-release lacrimal duct implant therapy. On the day of service the patient undergoes minor in-office or ambulatory surgical center (ASC) procedure. Topical anesthesia and antisepsis are applied, the punctum and canaliculus are dilated as needed, and a drug-eluting implant is inserted into the lacrimal duct using a delivery device. The provider documents informed consent, reason for implant, laterality, materials/drug used, dilation performed (if any), estimated blood loss (minimal), and immediate post-procedure instructions. The implant may be coded with 68841. Common workflow steps include pre-procedure counseling, medication reconciliation, topical anesthesia, dilation of the lacrimal duct if required, implant insertion, brief observation, and discharge with follow-up arranged for implant assessment or removal if indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing physician or other qualified provider professional work separate from facility technical component. |